– BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency – – NDA to be submitted mid-year for Translarna™ based on FDA feedback – SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S….